Loading…

Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial

The target blood pressure (BP) value is unclear for diabetic kidney disease (DKD). Therefore, we aimed to evaluate the effect of strict BP control or 'on treatment' BP on clinical outcomes in patients with DKD. A post-hoc analysis of the prespecified secondary outcomes of the FimAsartaN pr...

Full description

Saved in:
Bibliographic Details
Published in:Clinical hypertension 2024, 30(0), , pp.20-20
Main Authors: Park, Cheol Ho, Hong, Soon Jun, Kim, Sung Gyun, Shin, Seok Joon, Kim, Dong Ki, Lee, Jung Pyo, Han, Sang Youb, Lee, Sangho, Won, Jong Chul, Kang, Young Sun, Park, Jongha, Han, Byoung-Geun, Na, Ki-Ryang, Hur, Kyu Yeon, Kim, Yong-Jin, Park, Sungha, Yoo, Tae-Hyun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The target blood pressure (BP) value is unclear for diabetic kidney disease (DKD). Therefore, we aimed to evaluate the effect of strict BP control or 'on treatment' BP on clinical outcomes in patients with DKD. A post-hoc analysis of the prespecified secondary outcomes of the FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial, a randomized multicenter double-blind phase III trial. Eligible patients were aged ≥ 19 years with DKD. We assigned 341 participants with DKD to BP control strategy (standard-systolic BP [SBP] 
ISSN:2056-5909
1342-2154
2635-6325
2056-5909
DOI:10.1186/s40885-024-00280-x